Abstract: The present invention pertains to a process for the preparation of an arylphosphine of the formula R1OC—Ar—PR2R3 wherein Ar is aryl or heteroaryl; R1 is an alkoxy or amine group; and R2 and R3 are each any organic group; and each of the respective groups may optionally be substituted with any non-interfering group; which comprises the reaction of a sulfonyloxy compound of the formula R1OC—Ar—OSO2R4 wherein R4 is alkyl, haloalkyl, perhaloalkyl, aryl, aralkyl or alkaryl, with a phosphine of the formula HPR2R3, in a solvent and in the presence of a palladium catalyst and a base. The arylphosphine can then readily be converted to a chiral phosphine ligand.

Abstract: Disclosed is a method for closely linking a process for producing 2,6-naphthalene dicarboxylic acid (2,6-NDA) with a process for producing polyethylene naphthalate, thus eliminating the need for drying 2,6-NDA, handling solid 2,6-NDA, and optimizing particle size of 2,6-NDA which comprises: a) Adding an aqueous slurry of polymer grade 2,6-NDA directly into a process for making PEN, either by directly adding a stream from a 2,6 NDA process into a PEN process, or by adding water to polymer grade 2-6-NDA prior to adding the resulting slurry to a PEN process. b) Removing the slurry water during the first esterification reaction at the same time the water of reaction is removed.

Abstract: Novel chiral swallow-tailed liquid crystals synthesized from chiral material comprised of alkyl(s)-2-{6-[4-(4′-alkyloxyphenyl)benzoyloxy]-2-naphthyl}propionates having a rigid core, a chiral center directly linked to the rigid core, a chiral tail, and a swallow-tailed group linked to the chiral tail. The chiral center and the swallow-tailed group are arranged at the same side in the molecular structure of the chiral material. These structural characteristics enable the chiral material to have same property of threadholdless antiferroelectricity, and the advantage of simple manufacturing process. The chiral material shows an optimum application effect in liquid crystal displays.

Abstract: A method for manufacturing a color coupler used in a silver halide photographic light-sensitive material using an ammonium trihalide. Said method for manufacturing the color coupler comprising the following step: a step for halogenating a coupling position of a four equivalent coupler using a halogenating agent, wherein said halogenating agent is said ammonium trihalide.

Abstract: Provided are novel acetylene compounds which are useful as a component for a liquid crystal composition used for a liquid crystal element, a liquid crystal composition containing said compounds and a liquid crystal element using said liquid crystal composition. The acetylene compound is represented by Formula (1): n-CmH2m+1—C≡C—A—Z1—B—Y1—R1  (1) wherein m represents an integer of 2 to 24; R1 represents a linear or branched alkyl group, a linear or branched alkoxyalkyl group, a linear or branched alkenyl group, or a linear or branched alkenyloxyalkyl group each of which may be substituted with a halogen atom; R1 may have an asymmetric carbon atom, and the asymmetric carbon atom may be optically active; A and B represents a cyclic group such as a phenylene group, a biphenylene group, a naphthylene group and the like each of which may be substituted with a halogen atom.

Abstract: Disclosed is a process for the production and purification of dialkyl naphthalenedicarboxylate compounds wherein a crude naphthalenediacarboxylic acid is esterified with an alkanol such as methanol to produce a crude esterification product comprising dialkyl naphthalenedicarboxylate, starting materials and other compounds and the crude esterification product is purified by flash distillation to remove impurities which can cause fouling of conventional distillation equipment. A particularly useful diester is dimethyl 2,6-naphthalenedicarboxylate.

Abstract: Bi-aromatic compounds linked via a heteroethynylene radical are provided along with pharmaceutical and cosmetic compositions containing these compounds and methods for their use.

Abstract: This invention relates to compounds, pharmaceutical compositions, and methods of using compounds of the formula: A is O or S; R is C1-C10 straight or branched chain alkyl, C2-C10 straight or branched chain alkenyl, C2-C10 straight or branched chain alkynyl, aryl, heteroaryl, carbocycle, or heterocycle; D is a bond, or a C1-C3 straight or branched chain alkyl, C2-C3 straight or branched chain alkenyl, C2-C3 straight or branched chain alkynyl, wherein any of the carbon atoms of said alkyl, alkenyl, or alkynyl of D are optionally replaced with oxygen, nitrogen, or sulfur; and X is aryl, heteroaryl, carbocycle, or heterocycle.

Abstract: Process for the preparation of .alpha.-alkoxy-.alpha.-trifluoromethyl-arylacetic esters of the formula (I) ##STR1## wherein R is a component selected from the group consisting of C.sub.1 -C.sub.6 -alkyl, C.sub.2 -C.sub.6 -alkenyl, C.sub.3 -C.sub.7 -cycloalkyl, C.sub.6 -C.sub.10 -aryl and C.sub.1 -C.sub.6 -halogenoalkyl, R' is selected from the group consisting of C.sub.1 -C.sub.4 -alkyl, X is selected from the group consisting of halogen, C.sub.1 -C.sub.4 -alkyl, C.sub.2 -C.sub.4 -alkenyl, C.sub.6 -C.sub.10 -aryl or C.sub.1 -C.sub.4 -alkoxy and nitro, and n is zero or an integer from 1 to 3.

Abstract: A new family of inadone and tetralone tubulin-binding compounds (TBs) is disclosed. Unlike classical TBs, which inhibit mitosis among affected dividing cells, the TBs of the invention possess two unique properties: (1) they induce apoptosis among stationary phase (non-dividing) malignant cells, yet do not impair the viability of normal nonproliferating cells; and, (2) they affect cells which have acquired MDR more powerfully than they affect cells without MDR. Thus, the TBs of the invention provide means to target malignant cells for chemotherapy, even after previous therapies have failed, without affecting normal cells and tissues in the host.

Abstract: Complexes of a selected class of chiral ligands with molybdenum, tungsten or chromium, preferably molybdenum, are effective as catalysts in highly enantioselective and regioselective alkylation of allylic substrates. Such compositions provide a versatile and low-cost alternative to existing catalysts.

Abstract: The present invention relates to specific adamantyl or adamantyl group derivative containing retinoid compounds induce apoptosis of cancer cells. These adamantyl retinoid derivatives are useful for the treatment of many cancers and solid tumors, especially androgen-independent prostate cancer, skin cancer, pancreatic carcinomas, colon cancer, melanoma, ovarian cancer, liver cancer, small cell lung carcinoma, non-small cell lung carcinoma, cervical carcinoma, brain cancer, bladder cancer, breast cancer, neuroblastoma/glioblastoma, and leukemia. Also, the invention relates to novel adamantyl or adamantyl group derivative compounds which are useful as active agents for the treatment or prevention of keratinization disorders and other dermatological conditions, and other diseases.

Abstract: Supported bis(phosphorus) ligands are disclosed for use in a variety of catalytic processes, including the hydrocyanation of unsaturated organic compounds. Catalysts are formed when the ligands are combined with a catalytically active metal (e.g., nickel).

Abstract: Compounds of the formula ##STR1## where the symbols have the meaning describedin the application, have retinoid-like or retinoid antagonist-like biological activity.

Abstract: This invention relates to compositions for and methods of treating, preventing or ameliorating cancer and other proliferative diseases as well as methods of inducing wound healing, treating cutaneous ulcers, treating gastrointestinal disorders, treating blood disorders such as anemias, immunomodulation, enhancing recombinant gene expression, treating insulin-dependent patients, treating cystic fibrosis patients, inhibiting telomerase activity, treating virus-associated tumors, especially EBV-associated tumors, modulating gene expression and particularly augmenting expression of a tumor suppressor gene, inducing tolerance to an antigen and treating, ameliorating or preventing protozoan infection. The methods of the invention use metabolically stabilized oxyalkylene esters.

Abstract: Methods for reducing the fouling of process equipment used in the manufacture of aromatic compounds such as dimethyl-2,6-naphthalenedicarboxylate are disclosed. The methods require treating manufacturing process streams with a metal complexing agent. Novel compositions useful in the manufacture of aromatic materials such as dimethyl-2,6-naphthalenedicarboxylate also are disclosed.

Abstract: Disclosed is a polycyclic compound represented by the following formula (I):R.sup.1 --X.sup.1 --[A.sup.1 --X.sup.2 ]--[A.sup.2 --X.sup.3 ]--R.sup.2 (I)wherein R.sup.1 is a (halogenated) alkyl group of 6 to 16 carbon atoms, X.sup.1 is --O-- group or a single bond, A.sup.1 is a biphenylene group, a phenylene group or the like, A.sup.2 is 1-fluoro-3,4-dihydronaphthalene or the like, X.sup.2 and X.sup.3 are each --COO--, a single bond or the like, and R.sup.2 is an optically active group of 4 to 20 carbon atoms which has at least one asymmetric carbon atom. Also disclosed are a liquid crystal material consisting of the polycyclic compound, a liquid crystal composition comprising the liquid crystal material, and a liquid crystal element. This novel polycyclic compound is optically active and capable of being in a smectic phase in a wide temperature range including room temperature. The polycyclic compound can be used as a ferroelectric liquid crystal material or an antiferroelectric liquid crystal material.

Abstract: Ortho-substituted benzoylguanidines of the formula I ##STR1## in which R(1) to R(5) have the meanings given in the claims, are suitable as antiarrhythmic pharmaceuticals having a cardioprotective component for infarct prophylaxis and for infarct treatment and also for the treatment of angina pectoris. They also inhibit in a preventive manner the pathophysiological processes in the formation of ischemically induced damage, in particular in the illicitation of ischemically induced cardiac arrhythmias.

Abstract: Compounds of the formula ##STR1## the symbols have the meaning described in the specification.

Abstract: Compounds of the formula ##STR1## where the symbols have the meaning described in the application, have retinoid-like or retinoid antagonist-like biological activity.

Abstract: The invention relates to a process for the preparation of highly concentrated free-flowing and pumpable aqueous solutions of betaines by quaternization of a compound which contains tertiary amine nitrogen with a .omega.-halo carboxylic acid characterized in that 0.5-5% by weight of the final product, of a viscosity-reducing compound such as an alkali or alkaline earth metal citric acid salt is added to the reaction mixture before or during the quaternization reaction.

Abstract: Use of fluorinated polymers based on fluoropolyethers for the preparation of crosslinkable high dry formulations comprising a fluorinated part R.sub.F and optionally an hydrogenated part R.sub.H, not containing groups capable of linking by means of hydrogen bonds to basic acceptors, an hydrogenated part Rh.sub.1 and Rh.sub.2, wherein Rh.sub.1 is equal to or different from Rh.sub.2, and Rh.sub.1 and/or Rh.sub.2 being linking bonds containing at least a functional group capable of linking by means of hydrogen bonds with basic acceptors, the bonds joining the fluorinated part to the hydrogenated part being of ether C--O simple type, the terminals T'.sub.a and T" being such as to render the structure mono-, bi- or polyfunctional, and subsequent crosslinking of the fluorinated polymer, the monofunctional products being always in admixture with a resin having even a higher functionality than the described type; the preferred fluorinated products have the formula:T"--(Rh.sub.2).sub.y (R.sub.H).sub.x --R.sub.F --(R.

Abstract: Compounds containing two cyclic hydrocarbon moieties which are substituted to provide crosslinking functionality and which are linked to each other by secondary or tertiary oxycarbonyl containing moiety are basis for compositions which are cured to provide cured thermosets for encapsulation and underfill for electronic components that are thermally decomposable to allow repair, replacement, recovery or recycling of operative electronic components from assemblies that are inoperative.

Abstract: Certain novel substituted (5,6)-dihydroanthracenyl compounds of the general formula ##STR1## wherein A, n, p, R.sub.1, R.sub.2, R.sub.3, R.sub.4, R.sub.5, R.sub.6, R.sub.7 and R.sub.8 are as defined in the specification exhibit retinoid-like properties and are particularly useful in the prevention of post-surgical adhesions.

Abstract: Naphthalene derivatives of the fomula I ##STR1## in which: R.sup.1 is an alkyl or alkenyl radical which is unsubstituted, monosubstituted by CH or CF.sub.3 or monosubstituted by halogen and has 1 to 15 carbon atoms, it also being possible for one or more CH.sub.2 groups in these radicals to be replaced, in each case independently of one another, by --O--, --S--, ##STR2## --CO--, --CO--O--, --O--CO-- or --O--CO--O-- in such a manner that oxygen atoms are not linked directly to one another, ##STR3## m is 0, 1 or 2, n is 0 or 1, wherem+n is 1 or 2,Z.sup.1 and Z.sup.2 are each, independently of one another, --CH.sub.2 CH.sub.2 --, --C.tbd.C-- or a single bond,L.sup.1 and L.sup.2 independently of one another, are H or F,x is an alkyl or alkoxy radical which is unsubstituted, monosubstituted by CN or CF.sub.3 or substituted bi halogen and has 1 to 15 carbon atoms, or is OH, CN, SCN, OCN, NCS or Q--Y,whereQ is a single bond, (CF.sub.2).sub.r or O(CF.sub.2).sub.

Abstract: Compounds of the formulaY.sub.3 (R.sub.4)--X--Y.sub.1 (R.sub.1 R.sub.2)--Z--Y.sub.2 (R.sub.2)--A--Bwhere the symbols have the meaning defined in the specification, have retinoid, retinoid antagonist or retinoid inverse agonist type biological activity.

Abstract: Enantiomerically substantially pure compounds of the formula ##STR1## where R is H or lower alkyl of 1 to 6 carbons, or pharmaceutically acceptable salts thereof have retinoid-like biological activity. The enantimerically pure or substantially pure compound of the above formula where R is H, or a pharmaceutically acceptable salt thereof, is highly specific agonist of RXR retinoid receptors in preference over RAR receptors.

Abstract: The novel liquid crystal compounds of the present invention are represented by the following formulas ?I!-?II! and have tristable molecular orientation states and can be used for display devices and electrooptical devices. ##STR1## wherein R.sub.1 represents an alkyl group of 5-18 carbon atoms; R.sub.2 represents an alkyl group of 6-16 carbon atoms; R.sub.3 represents an alkyl group of 8-18 carbon atoms; R.sub.4 represents an alkyl group of 6-14 carbon atoms; Y represents ##STR2## and * indicates an optically active center.

Abstract: The present invention relates to a process for the preparation of compounds of the formula (1)R.sup.1 R.sup.2 R.sup.3 R.sup.4 R.sup.5 ArCOOR (1)in which R.sup.1, R.sup.2, R.sup.3, R.sup.4 and R.sup.5 are identical or different and are hydrogen, a halogen, an alkyl or alkoxy group having 1 to 6 carbon atoms or OR, NHR, NR.sub.2, SR or COOR, in which R is an alkyl radical having 1 to 4 carbon atoms, Ar is an aryl radical having 6 to 12 carbon atoms and the radical R shown in formula (1) has the above meaning, by reacting a compound of the formula (2)R.sup.1 R.sup.2 R.sup.3 R.sup.4 R.sup.5 ArCOOH (2)in which R.sup.1, R.sup.2, R.sup.3, R.sup.4 and R.sup.5 are identical or different and are hydrogen, a halogen, an alkyl or alkoxy group having 1 to 6 carbon atoms, OH, NH.sub.2, NHR, SH or COOH and Ar has the same meaning as in formula (1), with a sulfate of the formula (RO).sub.2 SO.sub.2, in which R has the above meaning, in the presence of a water-insoluble tertiary amine and water at a temperature of 10.degree.

Abstract: Provided is a naphthalene compound represented by the following Formula (1): ##STR1## wherein R.sub.1 and R.sub.2 each represent a linear or branched alkyl group having 1 to 20 carbon atoms, an alkoxyalkyl group having 2 to 20 carbon atoms or an alkenyl group having 2 to 20 carbon atoms which may be substituted with halogen atoms and have no asymmetric carbon atoms; A represents any of the groups represented by the following formulas: ##STR2## (wherein X.sub.1, X.sub.2, X.sub.3 and X.sub.4 each represent a hydrogen atom or a halogen atom); and z represents 0 or 1. The addition of this naphthalene compound to a liquid crystal composition makes it possible to improve various characteristics such as the high speed response property of the liquid crystal composition and the temperature dependency of the response time. The above naphthalene compound is useful as a liquid crystal material for liquid crystal compositions, particularly ferroelectric liquid crystal compositions.

Abstract: The invention concerns tachykinin antagonists. The compounds are neopeptides which have utility in treating disorders mediated by tachykinins. Such disorders are respiratory, inflammatory, gastrointestinal, ophthalmic, allergies, pain, vascular, diseases of the central nervous system, and migraine. Methods of preparing compounds and novel intermediates are also included. The compounds are expected to be especially useful in asthma and rheumatoid arthritis.

Abstract: The present invention is concerned with photo cross-linkable liquid crystalline compounds of the general formula ##STR1## wherein A.sup.1 and A.sup.2 each represent a cross-linkable, mesogenic residue,liquid crystalline mixtures which contain such compounds and their use in the cross-linked state as optical components.

Abstract: Photocross-linkable naphthyl derivatives include compounds of the formula: ##STR1## wherein R.sup.1 and R.sup.2 each independently signify a cross-linkable group;S.sup.1 and S.sup.2 signify --(CY.sub.2).sub.m -, --O(CY.sub.2).sub.m -, --(CY.sub.2).sub.m O--, --(CY.sub.2).sub.m COO--, --(CY.sub.2).sub.m OOC--, --(Si?(CH.sub.3).sub.2 !O).sub.m -, --OCH.sub.2 (Si?(CH.sub.3).sub.2 !O).sub.m Si?(CH.sub.3).sub.2 !CH.sub.2 O-- or --NHCH.sub.2 (Si?(CH.sub.3).sub.2 !O).sub.m Si?(CH.sub.3).sub.2 !CH.sub.2 NH--;Y signifies hydrogen, fluorine or methyl;a signifies 0 or 1;b signifies 1 or 2, with the proviso that a+b=2;m signifies a whole number of 1 to 16;A.sup.1 and A.sup.2 each independently signify 1,4-phenylene, which is optionally mono- or multiply-substituted with halogen, cyano, methyl, methoxy and/or acetyl, pyridine-2,5-diyl, pyrimidine-2,5-diyl, trans-1,4-cyclohexylene or trans-1,3-dioxane-2,5-diyl; andZ.sup.1 and Z.sup.2 each independently signify a single bond, --CH.sub.2 CH.sub.2 --, --OCH.sub.2 --, --CH.

Abstract: The invention provides a method of screening a substance for the ability to effect the formation of a retinoid X receptor homodimer comprising combining the substance and a solution containing retinoid X receptors and determining the presence of homodimer formation. Also provided is a method of screening a substance for an effect on a retinoid X receptor homodimer's ability to bind DNA comprising combining the substance with the homodimer and determining the effect of the compound on the homodimer's ability to bind DNA. A method of inhibiting an activity of a retinoid X receptor heterodimer comprising increasing the formation of a retinoid X receptor homodimer, thereby preventing the retinoid X receptor from forming a heterodimer and preventing the resulting heterodimer activity is also provided. A method of inhibiting an activity of a retinoid X receptor homodimer is also provided.

Abstract: Disclosed are derivatives of fluoroalkylethynyl- and difluoroalkylethynylbenzenes of the formula (I) herein. These compounds exhibit useful properties as liquid crystal compounds and are useful in nematic liquid crystal mixtures.

Abstract: Heptafluoroisobutenyl methyl ether having the following formula: ##STR1## is oxidized with ozone to produce perfluoro(2-methyl-1,2-epoxy-propyl) methyl ether. The resulting intermediate compound is allowed to react with an aromatic compound ArH to produce .alpha.,.alpha.-bis(trifluoromethyl)arylacetic acid methyl ester having the following formula: ##STR2## By hydrolysis, decarboxylation and further hydrolysis of the ester compound, .alpha.,.alpha.-bis(trifluoromethyl)arylacetic acid for use as raw materials for medicines, agricultural chemicals, liquid crystals, etc. or reagents for determining an optical purity can be obtained.

Abstract: Compounds of the formula ##STR1## where the symbols have the meaning described in the application, have retinoid-like or retinoid antagonist-like biological activity.

Abstract: The present invention is concerned with photo cross-linkable liquid crystalline compounds in the formula ##STR1## wherein for example: A,B,C,D,E,F independently is pyridine-2,5-diyl, pyrimidine-2,5-diyl, trans-1,4-cyclohexylene, trans-1,3-dioxane-2,5-diylZ.sup.1, Z.sup.2, Z.sup.7 independently is --(CH.sub.2).sub.s O--, --COO--, --(CH.sub.2).sub.s COO--Z.sup.3, Z.sup.4, Z.sup.8 independently is a single bond, --CH.sub.2 CH.sub.2 --, --CH.sub.2 O--Z.sup.5, Z.sup.6 independently is --(CH.sub.2).sub.s --m, n, q and r independently is 0, 1 or 2;s is a whole number of 1 to 16;R.sup.1, R.sup.2 independently is CH.sub.2 .dbd.CH--COO--, CH.sub.2 .dbd.C(CH.sub.3)--COO--R.sup.3 is H, CH, COOC.sub.n H.sub.2n+1, CnH.sub.2n+1 ; n=1 . . . 10X.sup.1, X.sup.2 and X.sup.3 independently is hydrogen, halogen, cyano or lower alkyl.The invention is also related to liquid crystalline mixtures and their use for electro-optical purpose.

Abstract: Compounds of formula (I) wherein R.sup.1 -R.sup.7, R.sup.10, X and the dotted bond have the meaning given in the specification, bind selectively to retinoid RXR receptors and are useful as antiproliferative agents for dermatological and oncological indications.

Abstract: A process is described for producing acetals comprising reacting an aldehyde or a ketone with an alcohol in the presence of a titanium compound having an acetylacetone as a ligand, or in the presence of a compound selected from the group consisting of stannous chloride dihydrate, cerium chloride hexahydrate and bismuth chloride. The process can be used in the synthesis of unstable acetals or when water exists in the reaction mixture, and therefore the process can be used for a wide variety of applications.

Abstract: A method for synthesizing a halogen-containing condensation product, the method comprising the step of:reacting a compound represented by Formula (I) with a compound represented by Formula (II) or (III) in the presence of a halogenating agent whereby dehydration condensation and halogenation are carried out, ##STR1##

Abstract: A process for the preparation of compounds of the formula (1) in which R.sup.1, R.sup.2 and R.sup.3 are as defined in the specification, which includes reacting alcohols or carboxylic acids of the formula (2) in which R.sup.1, R.sup.2 and R.sup.3 are as defined in the specification, with a fluorinating agent of the formula (3) as defined in the specification.

Abstract: A novel pyrimidine compound represented by the following Formulas (1) and (2), a liquid crystal composition containing said compound and a liquid crystal element having excellent characteristics such as high speed response, orientation and high contrast ratio. ##STR1## wherein R.sub.1 and R.sub.2 each represent a linear or branched alkyl or alkenyl group, an alkoxyl or alkenyloxy group; R.sub.3 and R.sub.4 each represent a linear or branched alkyl group or alkenyl group; A.sub.1 and A.sub.2 each represent a substituted or unsubstituted 1,4-phenylene group, a pyridine-2,5-diyl or trans-1,4-cyclohexylene group; X.sub.1 and X.sub.2 each represent a single bond, --COO--, --OCO--, --OCH.sub.2 or --CH.sub.2 O-- group; Y.sub.1 and Y.sub.2 each represent --COO-- or --OCO-- group; and a, b, p, q, m and n each represent 0 or 1, provided that a+b+p+q is not 0.

Abstract: Novel pharmaceutically/cosmetically-active polycyclic aromatic compounds have the structural formula (I): ##STR1## wherein Ar is a radical having one of the formulae (a)-(e): ##STR2## and are useful for the treatment of a wide variety of disease states, whether human or veterinary, for example dermatological, rheumatic, respiratory, cardiovascular and ophthalmological disorders, as well as for the treatment of mammalian skin and hair conditions/disorders.

Abstract: Compounds of the formula ##STR1## where the symbols have the meaning described in the application, have retinoid-like or retinoid antagonist-like biological activity.

Abstract: Compounds of the formula ##STR1## where the symbols have the meaning described in the application, have retinoid-like or retinoid antagonist-like biological activity.

Abstract: The present invention relates to catalytic asymmetric hydrogenation of phosphorus analogs of itaconic acid to synthesize novel optically active phosphono succinates.

Abstract: A liquid crystal compound of the formula (1) ##STR1## wherein R is a linear alkyl group having 6 to 12 carbon atoms,both X and Y are hydrogen atoms or one of X and Y is a fluorine atom and the other is a hydrogen atom,A is --CF.sub.3 or --C.sub.2 F.sub.5,m is an integer of 2 to 4,n is an integer of 2 to 4, andC* is an asymmetric carbon,having a ferrielectric phase in its phase sequence, or a ferrielectric liquid crystal composition containing the liquid crystal compound of the formula (1) having a ferrielectric phase, may be injected between substrates provided with nonlinear active elements, such as thin film transistors or diodes formed on each pixel, to form an active matrix liquid crystal display device.

Abstract: This document describes O-acyl-4-phenyl-cycloalkanols of general formula I ##STR1## wherein n denotes the number 0 or 1, m denotes the number 1 or 2, p denotes the number 0 or 1, R.sup.1 and R.sup.2 each denote hydrogen, lower alkyl, alkenyl or alkynyl, which may optionally also be substituted, or together with the nitrogen atom between them denote 5- to 7-membered saturated, monocyclic, heterocyclic rings which may optionally also be interrupted by an oxygen or sulphur atom or by an imino group, R.sup.3, R.sup.4, R.sup.5 and R.sup.6 denote hydrogen or lower alkyl, R.sup.5 additionally denotes lower alkoxy, R.sup.7 denotes hydrogen, cycloalkyl, phenyl or substituted phenyl, naphthyl, tetrahydronaphthyl, thienyl, furyl or pyridyl and A denotes a chemical bond or alkyl, alkenyl or alkynyl having up to 17 carbon atoms, and also processes for preparing them, pharmaceutical compositions containing these compounds and the use of these pharmaceutical compositions which intervene in cholesterol biosynthesis.

Abstract: Novel pharmaceutically/cosmetically-active polyaromatic amides have the structural formula (I): ##STR1## wherein Z is a radical --CO--NH-- or --NH--CO--, and are useful for the treatment of a wide variety of disease states, whether human or veterinary, for example dermatological, rheumatic, respiratory, cardiovascular and ophthalmological disorders, as well as for the treatment of mammalian skin and hair conditions/disorders.